当前位置: 首页 > 详情页

A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, 215000 Suzhou, China [2]Department of Radiation Oncology, Zhejiang Cancer Hospital, 310022 Hangzhou, China [3]Zhejiang Key Laboratory of Radiation Oncology, Hangzhou 310022, China
出处:
ISSN:

关键词: S-1 chemoradiotherapy esophageal cancer elderly

摘要:
Background: Concurrent chemoradiotherapy (CCRT) using conventional platinum-based doublets are often associated with significant incidence of toxic effects in elderly patients with esophageal cancer. We previously reported a phase I trial of CCRT using S-1, an oral 5-fluorouracil derivative, which yielded well safe and active outcomes. Methods: Patients with histologically confirmed esophageal cancer, who were age of 70 years or older with performance status (PS) score of 0-2 or age of 66 to 69 with PS score of 2, were eligible for this Phase II trial. Radiotherapy was delivered in 1.8 Gy per fraction to a total dose of 54 Gy. Concurrently, S-1 was administered at 70 mg/m(2) on days 1-14 and 29-42. The primary end point was 2-year overall survival rate. Results: Thirty patients were enrolled, and 28 patients completed the full course of radiotherapy. No grade 4 toxicity or treatment-related death occurred. The grade 3 toxicities included esophagitis (16.7%), leucopoenia (13.3%), neutropenia (10%), anaemia (3.3%), pneumonitis (3.3%) and fatigue (3.3%). The median progression-free survival time and median survival time was 19 and 24 months, respectively. The 2-year overall survival rate was 45.1%, which exceeded the predefined threshold of 2-year OS 35% and met the primary end point of the study. Conclusions: The results suggest that CCRT using S-1 is effective with mild toxicity in elderly patients with esophageal cancer. A phase III trial is needed to further evaluate this regimen.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 1 区 医学
小类 | 2 区 细胞生物学 2 区 肿瘤学
最新[2025]版:
JCR分区:
出版当年[2015]版:
Q1 CELL BIOLOGY Q1 ONCOLOGY
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, 215000 Suzhou, China [2]Department of Radiation Oncology, Zhejiang Cancer Hospital, 310022 Hangzhou, China [3]Zhejiang Key Laboratory of Radiation Oncology, Hangzhou 310022, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, 215000 Suzhou, China [2]Department of Radiation Oncology, Zhejiang Cancer Hospital, 310022 Hangzhou, China [3]Zhejiang Key Laboratory of Radiation Oncology, Hangzhou 310022, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17095 今日访问量:0 总访问量:920 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院